Get the Stockscreener App
22.36
7.53%
-1.82
Pre-market:
22.60
0.24
+1.07%
Moderna Inc stock is traded at $22.36, with a volume of 18.58M.
It is down -7.53% in the last 24 hours and down -17.91% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$24.18
Open:
$24.45
24h Volume:
18.58M
Relative Volume:
1.63
Market Cap:
$8.70B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.5613
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-10.42%
1M Performance:
-17.91%
6M Performance:
-20.11%
1Y Performance:
-39.47%
1-Day Range:
$22.32
$24.91
1-Week Range:
$22.32
$25.33
52-Week Range:
$22.32
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
22.36 | 9.45B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth - BioSpace
$1.5 Billion Loan Aims to Help Moderna Grow and Invest in Research - MarketScreener
Rx Rundown: Johnson & Johnson, Avadel Pharmaceuticals, Moderna and more - Medical Marketing and Media
Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix… - MarketScreener
22,410 Shares in Moderna, Inc. $MRNA Acquired by Catalyst Funds Management Pty Ltd - MarketBeat
Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today - inkl
Health Care Down, But not by Much, Amid Deal Activity -- Health Care Roundup - MarketScreener
IR Insights: Recapping Our 2025 Analyst Day - Moderna
Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines - Stocktwits
Moderna stock hits 52-week low at 23.04 USD By Investing.com - Investing.com India
Moderna stock hits 52-week low at 23.04 USD - Investing.com
Moderna projects 10% growth next year; lifts outlook for year-end liquidity - MSN
Moderna secures $1.5B lifeline as it looks to break even in 2028 - BioPharma Dive
Moderna promises pipeline progress and healthy growth - The Pharma Letter
Moderna (MRNA) Unveils Pipeline Progress and Strategic Updates a - GuruFocus
Moderna gets breathing room with $1.5 billion loan from Ares - The Boston Globe
Moderna to onshore drug product manufacturing to Massachusetts - Yahoo Finance
Moderna Trims Pipeline and Takes On $1.5 Billion Loan as Cash Worries Loom - Barron's
Moderna : Presentation (Moderna 2025 Analyst Day FINAL PDF 48 ) - MarketScreener
Moderna takes $1.5 billion loan, expects 10% revenue growth next year - The Mighty 790 KFGO
Moderna (MRNA) Developments: Vaccine Approvals and Strategic Adjustments - GuruFocus
Moderna (MRNA) Projects Revenue Growth and Strategic Investments - GuruFocus
Moderna (MRNA) Reveals Strategic Plans for Growth and Innovation - GuruFocus
Moderna (MRNA) Targets Major Vaccine Expansion by 2028 - GuruFocus
Moderna (MRNA) Optimizes Global Manufacturing for Future Growth - GuruFocus
Moderna secures $1.5 billion credit facility from Ares Management By Investing.com - Investing.com Australia
Moderna secures $1.5 bln loan, targets up to 10% rev growth in 2026 - MarketScreener
Moderna outlines growth strategy targeting 10% revenue increase in 2026 - Investing.com
Moderna (MRNA) Projects Revenue Growth and Strategic Financial M - GuruFocus
Moderna projects 10% growth next year (MRNA:NASDAQ) - Seeking Alpha
Moderna (MRNA) Unveils Strategic Growth Plans and Pipeline Updates - GuruFocus
Moderna (MRNA) Secures $1.5 Billion Loan to Enhance Financial Fl - GuruFocus
Moderna Announces Pipeline Progress and Strategy Update - TipRanks
Moderna, Inc. Announces Pipeline and Strategy Updates at Analyst Day - TradingView
Moderna Bets Big On The Future With New $1.5 Billion Loan - Finimize
Moderna Gets Breathing Room With $1.5 Billion Loan From Ares - Bloomberg.com
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management - ACCESS Newswire
Moderna stock rises after outlining growth strategy targeting 10% revenue growth by 2026 - Investing.com Canada
Cambridge-based Moderna lands $1.5B loan, unveils growth plans - NBC Boston
Moderna secures $1.5B loan, eyes cash breakeven in 2028 - The Business Journals
Is Moderna Inc. stock trading near support levelsSwing Trade & Trade Opportunity Analysis - newser.com
PNC Financial Services Group Inc. Has $1.56 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Can Moderna Inc. stock hit record highs again2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Moderna Will Talk to Analysts on Thursday. It Needs to Stop Burning Through Cash. - Barron's
Moderna to complete US mRNA manufacturing network with $140 million investment - Reuters
Moderna to onshore drug production at Norwood facility as part of $140M expansion - The Business Journals
Moderna (MRNA) Expands U.S. Manufacturing with $140M Investment - GuruFocus
Moderna completes end-to-end mRNA manufacturing network in U.S. - Seeking Alpha
Moderna (MRNA) Expands U.S. Manufacturing with New Facility - GuruFocus
Moderna expands US manufacturing with new drug product facility By Investing.com - Investing.com Australia
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):